Compare BRID & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | GNLX |
|---|---|---|
| Founded | 1932 | 2001 |
| Country | United States | United States |
| Employees | 668 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 110.4M |
| IPO Year | 1995 | 2022 |
| Metric | BRID | GNLX |
|---|---|---|
| Price | $5.83 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 3.6K | ★ 266.4K |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $5.65 | $2.29 |
| 52 Week High | $8.62 | $8.54 |
| Indicator | BRID | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 44.65 |
| Support Level | N/A | $2.34 |
| Resistance Level | $6.14 | $2.86 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 30.10 | 39.29 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.